These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20620881)

  • 1. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics.
    Correll CU
    Eur Psychiatry; 2010 Jun; 25 Suppl 2():S12-21. PubMed ID: 20620881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical stakes when switching from one antipsychotic to another].
    Constant É
    Encephale; 2013 Dec; 39(6):439-44. PubMed ID: 24238644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.
    Buckley PF
    J Clin Psychiatry; 2007; 68 Suppl 6():5-9. PubMed ID: 17650053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems when switching antipsychotics].
    Maltesen HR; Lublin HK
    Ugeskr Laeger; 2012 Jan; 174(5):264-7. PubMed ID: 22293072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.
    Cerovecki A; Musil R; Klimke A; Seemüller F; Haen E; Schennach R; Kühn KU; Volz HP; Riedel M
    CNS Drugs; 2013 Jul; 27(7):545-72. PubMed ID: 23821039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotic agents: a critical review.
    Worrel JA; Marken PA; Beckman SE; Ruehter VL
    Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ
    J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.
    Aringhieri S; Carli M; Kolachalam S; Verdesca V; Cini E; Rossi M; McCormick PJ; Corsini GU; Maggio R; Scarselli M
    Pharmacol Ther; 2018 Dec; 192():20-41. PubMed ID: 29953902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The art and science of switching of antipsychotic medications, part 1.
    Weiden PJ; Young AH; Buckley PF
    J Clin Psychiatry; 2006 Nov; 67(11):e15. PubMed ID: 17201045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine levels after clozapine discontinuation.
    de Leon J; Henighan V; Stanilla JK; Simpson GM
    J Clin Psychopharmacol; 1996 Apr; 16(2):193-4. PubMed ID: 8690839
    [No Abstract]   [Full Text] [Related]  

  • 15. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
    Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
    Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.